AUTHOR=Lobov Arseniy A. , Boyarskaya Nadezhda V. , Kachanova Olga S. , Gromova Ekaterina S. , Shishkova Anastassia A. , Zainullina Bozhana R. , Pishchugin Alexander S. , Filippov Alexey A. , Uspensky Vladimir E. , Malashicheva Anna B. TITLE=Crenigacestat (LY3039478) inhibits osteogenic differentiation of human valve interstitial cells from patients with aortic valve calcification in vitro JOURNAL=Frontiers in Cardiovascular Medicine VOLUME=9 YEAR=2022 URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.969096 DOI=10.3389/fcvm.2022.969096 ISSN=2297-055X ABSTRACT=
Calcific aortic valve disease (CAVD) is one of the dangerous forms of vascular calcification. CAVD leads to calcification of the aortic valve and disturbance of blood flow. Despite high mortality, there is no targeted therapy against CAVD or vascular calcification. Osteogenic differentiation of valve interstitial cells (VICs) is one of the key factors of CAVD progression and inhibition of this process seems a fruitful target for potential therapy. By our previous study we assumed that inhibitors of Notch pathway might be effective to suppress aortic valve leaflet calcification. We tested CB-103 and crenigacestat (LY3039478), two selective inhibitors of Notch-signaling, for suppression of osteogenic differentiation of VICs isolated from patients with CAVD